Little Journey, the digital health company transforming pediatrics with personalised family support solutions, is pleased to announce the appointment of Craig Serra as a Life Sciences Advisor.
Craig brings decades of leadership in clinical trial innovation, with a track record spanning Flatiron Health, Novartis, IQVIA, and Pfizer, and currently serving as Executive Data Management and Clinical Systems Consultant to Amgen. At Flatiron Health, Craig built the commercial and partnerships function for its Clinical Research business, helping launch ground-breaking solutions in prospective evidence generation, protocol optimization, and point-of-care patient matching.
Craig's appointment marks a strategic milestone in Little Journey’s expansion across global pediatric studies - helping sponsors deliver more efficient, patient-centred trials.
"Pediatric drug development is its own special place. Clinical research with children is a unique challenge, and it deserves a uniquely thoughtful solution," Craig said.
"Little Journey is doing something I’ve never seen before: giving children and families meaningful preparation, personalisation, and ownership of their trial experience."
Commenting on the value of Little Journey as a tech-enabled solution for global pharma, Craig added:
"Not only is it the right thing to do, but it is central to recruitment and retention. If you don’t retain participants, you have to over-enroll. That makes trials longer and more expensive. Little Journey offers a simple, scalable way to change that."
Craig's passion for improving pediatric research is deeply personal. His daughter Grace was diagnosed with bilateral Wilms tumors, a childhood kidney cancer, at three years old.
Through his first-hand experience into how frightening and disorienting healthcare can be - especially for young patients and their families - Craig has become a vocal advocate for patient empowerment and digital innovation.
"I spoke at the MSK Kidney Cancer Consortium two years ago and listed the years that the drugs Grace was on were approved, for adults of course. 1960s. 1970s. Pediatric approvals came much later. Within the relatively small world of pediatric drug development, we can and have to do better." Craig concluded.
Craig will support Little Journey’s continued expansion into global pediatric trials by advising on trial design, sponsor strategy, and regulatory engagement. His appointment coincides with the launch of new platform features designed to improve retention, adherence, and engagement at scale, improving trial efficiencies.
“We’re thrilled to welcome Craig as an official part of the Little Journey team,” said Dr Chris Evans, CEO and co-founder of Little Journey. “He brings not only deep operational expertise in the industry but also shares our commitment to improving the human side of pediatric research.”